News Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Delayed Nasdaq Other stock markets 12:55:36 2024-04-23 pm EDT			5-day change	1st Jan Change
1.067 ^USD	+14.61%		+7.97%	+54.18%

Apr. 04	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	CI
Apr. 02	Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference	Apr. 09	AQ
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment	Apr. 04	AQ
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	Apr. 04	CI
Sensei Biotherapeutics : Company Presentation April 2024	Apr. 02	PU
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	Apr. 02	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium	Mar. 22	AQ
Keystone Symposia 2024: Preclinical data for SNS-101	Mar. 21	PU
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences	Mar. 06	AQ
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights	Feb. 28	AQ
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Sensei Biotherapeutics, Inc. Announces Management Changes	Feb. 08	CI
Sensei Biotherapeutics to Present at Upcoming Conferences	Feb. 07	AQ
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones	Jan. 04	AQ
HC Wainwright Initiates Sensei Biotherapeutics With Buy Rating, Price Target is $4	Dec. 04	MT
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 07	CI
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 07	AQ
Sensei Biotherapeutics : Regulation FD Disclosure - Form 8-K	Nov. 06	PU
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..	Nov. 05	CI
Sensei Biotherapeutics : Company Presentation November 2023	Nov. 03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 06:59 am EST